Similar Papers

Paper Title
Journal
Date
Author
The Impact of Infections in Patients Treated with Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma.
Abdullah Esmail ... Maen Abdelrahim
Journal of clinical medicine | VOL. 13
Abdullah Esmail, et. al.Abdullah Esmail ... Maen Abdelrahim
23 Aug 2024
Prognostic significance of cutaneous immune-related adverse events in patients with melanoma and other cancers on immune checkpoint inhibitors
Leah L Thompson ... Steven T Chen
Journal of the American Academy of Dermatology | VOL. 86
Leah L Thompson, et. al.Leah L Thompson ... Steven T Chen
17 Mar 2021
Immune-Related Adverse Events and Outcomes in Patients with Advanced Non–Small Cell Lung Cancer: A Predictive Marker of Efficacy?
Jordi Remon ... Benjamin Besse
Journal of Thoracic Oncology | VOL. 14
Jordi Remon, et. al.Jordi Remon ... Benjamin Besse
23 Apr 2019
Association between prior radical surgery (RS) and outcomes with immune checkpoint inhibitor (ICI) therapy for advanced urothelial carcinoma (aUC).
Dimitrios Makrakis ...
Journal of Clinical Oncology | VOL. 39
Dimitrios Makrakis, et. al.Dimitrios Makrakis ...
20 Feb 2021
View more papers

More From: Journal for ImmunoTherapy of Cancer

Paper Title
Journal
Date
Author
Real-world outcomes with tisagenlecleucel in aggressive B-cell lymphoma: subgroup analyses from the CIBMTR registry
Daniel J Landsburg ... Cameron J Turtle
Journal for ImmunoTherapy of Cancer | VOL. 13
Daniel J Landsburg, et. al.Daniel J Landsburg ... Cameron J Turtle
09 Feb 2025
Phase I study of efineptakin alfa (NT-I7) for the treatment of Kaposi sarcoma
Ramya Ramaswami ... Chia-Ching Jackie Wang
Journal for ImmunoTherapy of Cancer | VOL. 13
Ramya Ramaswami, et. al.Ramya Ramaswami ... Chia-Ching Jackie Wang
06 Feb 2025
Complete metabolic response as early predictor of long-term efficacy after adoptive T cell therapy using tumor-infiltrating lymphocytes
Troels Holz Borch ... Inge Marie Svane
Journal for ImmunoTherapy of Cancer | VOL. 13
Troels Holz Borch, et. al.Troels Holz Borch ... Inge Marie Svane
06 Feb 2025
Pembrolizumab hybrid dosing is non-inferior to flat dosing in advanced non-small cell lung cancer: a real-world, retrospective bicenter cohort study
Michiel M Smeenk ... Willemijn S M E Theelen
Journal for ImmunoTherapy of Cancer | VOL. 13
Michiel M Smeenk, et. al.Michiel M Smeenk ... Willemijn S M E Theelen
06 Feb 2025
View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.